Skip to Content

Infergen (interferon alfacon-1) Disease Interactions

There are 10 disease interactions with Infergen (interferon alfacon-1):

Major

Interferon alfa (applies to Infergen) renal dysfunction

Major Potential Hazard, High plausibility.

Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Interferon- alfa (applies to Infergen) autoimmune diseases

Major Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder

Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Interferon-alfa (applies to Infergen) hepatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease

Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy. Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment. Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease. Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
Major

Interferons (applies to Infergen) cardiac disease

Major Potential Hazard, High plausibility. Applicable conditions: Ischemic Heart Disease, Arrhythmias, Congestive Heart Failure

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
  3. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  4. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
View all 4 references
Major

Interferons (applies to Infergen) CNS dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Psychosis, Parkinsonism, Seizures

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  3. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  4. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
View all 4 references
Major

Interferons (applies to Infergen) depression

Major Potential Hazard, Moderate plausibility.

Interferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.

References

  1. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  2. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
  3. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  4. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
View all 4 references
Major

Interferons (applies to Infergen) thyroid dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Hypothyroidism, Hyperthyroidism

Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferon alfa (applies to Infergen) diabetes mellitus

Moderate Potential Hazard, Moderate plausibility.

Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients. Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus. Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferons (applies to Infergen) myelosuppression

Moderate Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferons (applies to Infergen) peripheral neuropathy

Moderate Potential Hazard, Moderate plausibility.

Paresthesia and numbness have been reported during interferon therapy. Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.

Infergen (interferon alfacon-1) drug interactions

There are 168 drug interactions with Infergen (interferon alfacon-1)

More about Infergen (interferon alfacon-1)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.